Atlas Blog

Expert-led insights on
FDA compliance

Insights on FDA inspections, compliance strategy, and regulatory intelligence from the Atlas team.

Cleaning validation acceptance criteria cover: 10 ppm, 1/1000 dose and HBEL limits, with 237 of 774 FDA Part 211 drug inspections citing 21 CFR 211.67 and 40.5% of those ending OAI.
CAPA & Quality Systems

Cleaning validation acceptance criteria: 10 ppm, 1/1000 dose, HBEL and a worked MACO example

How cleaning validation acceptance criteria are set: the three legacy limits from FDA's 1993 inspection guide (10 ppm, 1/1000 of the dose, visually clean), the health-based exposure limit (PDE) approach in the EMA 2014 guideline and its 2018 questions and answers, a worked MACO to swab limit calculation with illustrative numbers, swab and rinse recovery, detergent and microbial limits, the three-run convention, and Atlas data on 21 CFR 211.67 citations and OAI outcomes at 774 drug inspections from January 2025 to September 2026.

Read more
Every USFDA warning letter to India, 2025 to 2026: 34 letters, 23 citing the quality unit, 16 to facilities already on Import Alert 66-40, and a 174-day median from inspection to letter.
Warning Letters & Enforcement

USFDA warning letters to Indian companies: all 34 CGMP letters from 2025 and 2026

A data roundup of the 34 FDA CGMP warning letters issued to facilities in India from January 1, 2025 to October 14, 2026: a full table by company, city and state, letter date, product type and main charges; counts by year and state; the violations FDA cites most often; the median gap from inspection to letter; India's OAI rate against the US; and links to each facility's Atlas inspection record where it is public.

Read more
OOS vs OOT cover: 1,525 FDA inspections cited an out-of-specification failure, and 34.2% of them ended OAI against 14.9% of the rest, Atlas data October 2026.
CAPA & Quality Systems

OOS vs OOT: what separates them, how FDA investigates OOS, and what investigators cite

The difference between an out-of-specification (OOS) result and an out-of-trend (OOT) result in pharma, where OOT guidance comes from when no FDA regulation defines it, the Phase I and Phase II investigation in FDA's OOS guidance with its retesting, resampling, averaging and outlier rules, how an OOS result feeds CAPA under 21 CFR 211.192, and what FDA cited at 1,525 drug inspections that recorded an OOS-related citation between October 2008 and September 2026.

Read more
ICH Q7 cover: GMP for active pharmaceutical ingredients section by section, with 26 FDA API warning letters from January 2025 to September 2026, 14 of them to Indian firms and 7 to Chinese firms.
GMP & GxP Compliance

ICH Q7: GMP for active pharmaceutical ingredients, section by section, with FDA data

ICH Q7 is the GMP guideline for active pharmaceutical ingredients. This guide lays out all 20 sections in one table, explains where Q7 starts to apply (the step where the API starting material enters the process), sets Q7 against 21 CFR Part 211, covers the 2015 Q7 questions and answers document, and reads 26 FDA API CGMP warning letters issued from January 2025 to September 2026 by country, inspection outcome and the Q7 sections behind each charge.

Read more
ISO 14971 risk management and the QMSR citations behind it: 377 device inspections, 39.5% citing risk clause 7.1 or 4.1.2, against 13.7% under the QSR in 2025.
Medical Devices

ISO 14971: the risk management process step by step, and what FDA cites under the QMSR

ISO 14971:2019 is the international standard for risk management of medical devices. This guide walks through its process clause by clause (plan, analysis, evaluation, control, overall residual risk, review, production and post-production), explains what the ISO/TR 24971:2020 guidance adds, and shows how the standard connects to FDA's QMSR, which incorporates ISO 13485 by reference from February 2, 2026 but does not incorporate ISO 14971. It adds Atlas data on what FDA investigators cited: risk management clauses at 149 of 377 device inspections with citations from February 4 to October 1, 2026 (39.5%), against 13.7% for the closest QSR section in 2025.

Read more
The 10 most common FDA 483 observations ranked by citation: 211.192 investigations cited at 34.4% of 836 drug inspections from January 2025 to June 2026, with OAI rates for each.
FDA Form 483s

The most common FDA 483 observations: the top 10, ranked from 2025 to 2026 data

A ranked top 10 of the most common FDA Form 483 observations for drug manufacturers, built from 836 drug inspections with posted citations that ended between January 2025 and June 2026. Each entry gives the 21 CFR section, what it means in plain English, how often FDA cited it, how often inspections citing it were classified OAI, a recent Form 483 that shows it, and one prevention point. Includes the top 5 device observations under the QMSR, how a Form 483 differs from a warning letter, and where to find recent 483s.

Read more
Container closure integrity testing cover: 95 FDA inspections cited 21 CFR 211.94 between October 2008 and September 2026, and 52.6% of them ended OAI.
CAPA & Quality Systems

Container closure integrity testing: USP 1207 methods, stability, and what FDA cites

What container closure integrity testing (CCIT) proves, how the USP <1207> family sorts deterministic and probabilistic leak tests, when CCIT is expected for sterile products and stability programs, how FDA's 2008 guidance lets a CCI test replace the sterility test on stability, and what FDA cited at 95 drug inspections that recorded a 21 CFR 211.94 container and closure citation between October 2008 and September 2026.

Read more
Electronic batch record cover: 774 Part 211 drug inspections, 296 citing 211.192 and 70 citing 211.188, with a 57.1% OAI rate when 211.188 is cited against 24.9% without.
Data Integrity & CSV

Electronic batch record (EBR): what 21 CFR 211.188 and Part 11 require, and what FDA cites

An electronic batch record (EBR) is the computerized version of the batch production and control record that 21 CFR 211.188 requires for every batch of drug product. This guide separates the master production record (211.186) from the batch production record (211.188), compares EBR and paper in a table, sets out what Part 11 and 211.68 add, explains what the quality unit still reviews under 211.192 when a team uses review by exception, covers validation, and shows how often FDA cited batch record sections at 774 drug inspections from January 2025 to October 2026.

Read more
Process performance qualification (PPQ) cover: FDA Stage 2 protocol and batch count, with Form 483 data showing 40 of 774 Part 211 drug inspections cited 211.110(a) and 50% ended OAI.
CAPA & Quality Systems

Process performance qualification (PPQ): the protocol, the batch count, and what Form 483s cite

Process performance qualification (PPQ) is the second element of Stage 2 in FDA's January 2011 process validation guidance. This guide covers what a PPQ protocol must contain, why FDA sets no fixed number of PPQ batches while EU GMP Annex 15 treats three as a generally acceptable minimum, how to set sampling and acceptance criteria, how PPQ differs from IQ, OQ and PQ, when PPQ batches can be released, when PPQ is repeated, and what FDA investigators cited under 21 CFR 211.110(a) at 40 of 774 Part 211 drug inspections closed January 2025 to September 2026.

Read more
FDA Purple Book cover: biosimilars, exclusivity and the facility behind each license, with 0 of 47 vaccine inspections ending OAI, BLAs drawing 20 of 48 complete response letters in 2025, and 2,775 biologics Form 483s.
FDA Databases & Guidance

The FDA Purple Book: what it lists, how to search it, and the facility behind every license

A guide to the FDA Purple Book: what it lists under PHS Act section 351(k)(9) (licensed biological products, reference products, biosimilars, interchangeables, exclusivity dates and the patent lists added by the 2020 law), how to search it step by step, a Purple Book vs Orange Book table, and what interchangeability means. It closes with the facility side of licensure: 21 CFR 601.20(d), Atlas inspection outcomes by FDA program from January 2025 to October 2026 (vaccine facilities 51.1% VAI, 0 of 47 OAI; drug quality 15.7% OAI), complete response letter counts by application type, and named biologics facility records.

Read more
Revised Schedule M vs US CGMP cover: 13 Parts in the rule, 2,574 Indian facilities in the Atlas FDA record, and 14% of Indian drug quality inspections classified OAI against 19% in the US.
GMP & GxP Compliance

Schedule M (India GMP) vs US CGMP: the revised rule, clause by clause, with FDA data from India

What revised Schedule M of India's Drugs Rules, 1945 requires, read from Gazette notification G.S.R. 922(E) and its later amendments: the 13 Parts, the turnover-based deadlines and the December 31, 2025 extension for small and medium manufacturers. The rule is set clause by clause against 21 CFR Part 211, then against FDA's record at Indian drug facilities: 257 drug quality inspections from January 2025 to October 2026, their NAI, VAI and OAI split, and the Part 211 sections cited most.

Read more
Aseptic processing cover: 98 of 774 FDA Part 211 drug inspections cited 21 CFR 211.113(b) from January 2025 to September 2026, with 54.1% ending OAI and 62.2% also citing 211.192.
Inspection Readiness

Aseptic processing: FDA guidance, the 211.113(b) record, and what investigators cite

What aseptic processing is and how it differs from terminal sterilization, what FDA's 2004 aseptic processing guidance and 21 CFR 211.113(b) and 211.42(c)(10) require, how FDA investigators worded the 211.113(b) citation at 98 of 774 Part 211 drug inspections from January 2025 to September 2026, which sections came with it, and the six files that make up a defensible 211.113(b) record.

Read more
Process validation cover: FDA's three stages from the 2011 guidance, with 275 of 774 Part 211 drug inspections citing 21 CFR 211.100 or 211.110 and 43.6% of those ending OAI, January 2025 to September 2026.
CAPA & Quality Systems

Process validation: FDA's three stages, the batch question, and what 483s cite

What process validation is, the three stages in FDA's January 2011 guidance (process design, process qualification, continued process verification), how many PPQ batches FDA and EU GMP Annex 15 expect, how process validation differs from IQ, OQ and PQ, and how often FDA investigators cited 21 CFR 211.100 and 211.110 at 774 drug inspections that closed between January 2025 and September 2026.

Read more